Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)

Inclusion Criteria: * Male or female * Histologically or cytologically 3b or 4 (metastatic) non-small cell lung cancer. Patients must meet any subcriteria as detailed in the protocol. * Age greater than or equal to 18 years old * ECOG performance status of 0 to 1 * Prior diagnosis of brain metastases from NSCLC eligible provided that the brain metastases have been adequately treated, patient is neurologically stable and no new or progressive brain metastases identified. * Meets protocol requirements for specified laboratory values * Written informed consent * Appropriate use of effective contraception if of childbearing potential * Prior basal cell carcinoma or carcinoma in-situ of the cervix are eligible provided they have been treated with no evidence of disease Exclusion Criteria: * Prior chemotherapy for any stage of NSCLC * Prior surgery or radiation therapy within the last 2 weeks or incomplete recovery from prior procedures or therapy * Concurrent treatment or treatment within the last 2 years for any other malignancy * Grade 2 or greater nausea or Grade 1 or greater vomiting (despite antiemetic medication) * Medical conditions that would interfere with taking oral medications * Patients with bone metastases as the only site of disease * Pregnant or nursing women * Known HIV positivity or AIDS-related illness * Patients with significant QTc prolongation at baseline